Non-alcoholic Steatohepatitis Clinical Trial
Official title:
The Effect of Semaglutide in Subjects With Non-cirrhotic Non-alcoholic Steatohepatitis
Semaglutide is a medicine studied in patients with NASH. Semaglutide is a well-known medicine, which is already used by doctors to treat type 2 diabetes in many countries. Participants will either get semaglutide or a dummy medicine - which treatment participants get is decided by chance. Participants will need to inject themselves with medicine under the skin. Participants will need to do this once a week. The study will last for about 5 years. Participants will have up to 21 clinic visits and 9 phone calls with the clinical staff during the study. Some of the clinic visits may be spread over more than one day. Participants with other chronic liver diseases cannot take part in this study. Women cannot take part in the study if they are pregnant, breast-feeding or plan to become pregnant during the study period.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05945537 -
A Study of INI-822 in Healthy Volunteers and Participants With Non-alcoholic Steatohepatitis (NASH) or Presumed NASH
|
Phase 1 | |
| Recruiting |
NCT05462353 -
Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 Tablets in Adult Patients With NASH
|
Phase 2 | |
| Recruiting |
NCT05065593 -
The Effect of Aerobic and Resistant Exercise Training in Patients With Non-Alcoholic Steatohepatitis
|
N/A | |
| Terminated |
NCT04171765 -
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-Alcoholic Steatohepatitis
|
Phase 2 | |
| Recruiting |
NCT04365855 -
The Olmsted NAFLD Epidemiology Study (TONES)
|
N/A | |
| Active, not recruiting |
NCT02912260 -
Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)
|
Phase 2 | |
| Recruiting |
NCT06054815 -
Study to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed NASH
|
Phase 2 | |
| Completed |
NCT02784444 -
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC-0602K in Patients With NASH
|
Phase 2 | |
| Not yet recruiting |
NCT06160271 -
Study of Liver Fibrosis Stage Assessment by Fibroblast Activation Protein Imaging in Patients With Biopsy for Suspected or Proven Nonalcoholic Steatohepatitis
|
Phase 2 | |
| Active, not recruiting |
NCT05573204 -
Comparative Study Between Obeticholic Acid Versus Vitamin E in Patients With Non-alcoholic Steatohepatitis
|
Phase 2 | |
| Completed |
NCT04042142 -
Glucagon Resistance in Patients With NAFLD
|
N/A | |
| Completed |
NCT04657523 -
Ultrasound-Based Liver Fat Quantification (LFQ) Pilot Study
|
N/A | |
| Completed |
NCT04142424 -
A Study to Understand the Safety, Tolerability, and Activity of Drug in Body Over a Period of Time of AZD2693, in Subjects of Non-Childbearing Potential in Overweight But Otherwise Healthy Subjects, and Healthy Chinese and Japanese Subjects
|
Phase 1 | |
| Terminated |
NCT02787304 -
Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH)
|
Phase 2 | |
| Recruiting |
NCT04666402 -
Integrated Diagnostics for Early Diagnosis of Liver Disease
|
||
| Completed |
NCT02528305 -
The Effect of HIT in Patients With Non-alcoholic Fatty Liver Disease/Steatohepatitis
|
N/A | |
| Recruiting |
NCT01056133 -
Effect of Fish-oil on Non-alcoholic Steatohepatitis (NASH)
|
Phase 2 | |
| Completed |
NCT04806750 -
Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
|
Phase 2 | |
| Completed |
NCT02960204 -
Emricasan, an Oral Caspase Inhibitor, in Subjects With NASH Cirrhosis and Severe Portal Hypertension
|
Phase 2 | |
| Recruiting |
NCT05751720 -
Effect on Non-Alcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus With Gastric Inhibitory Polypeptide/Glucagon Like Peptide-1 Analogue
|
Phase 1/Phase 2 |